The Effects of Vitamin D supplementation on Hepatic Dysfunction, Vitamin D Status, and Glycemic Control in Children and Adolescents with Vitamin D Deficiency and Either Type 1 or Type 2 Diabetes Mellitus

Benjamin U. Nwosu
University of Massachusetts Medical School

Et al.

Let us know how access to this document benefits you.
Follow this and additional works at: https://escholarship.umassmed.edu/peds_endocrinology

Part of the Endocrinology, Diabetes, and Metabolism Commons, and the Pediatrics Commons

Repository Citation
Nwosu BU, Maranda L. (2014). The Effects of Vitamin D supplementation on Hepatic Dysfunction, Vitamin D Status, and Glycemic Control in Children and Adolescents with Vitamin D Deficiency and Either Type 1 or Type 2 Diabetes Mellitus. Endocrinology/Diabetes. https://doi.org/10.1371/journal.pone.0099646.
Retrieved from https://escholarship.umassmed.edu/peds_endocrinology/46

This material is brought to you by eScholarship@UMMS. It has been accepted for inclusion in Endocrinology/Diabetes by an authorized administrator of eScholarship@UMMS. For more information, please contact Lisa.Palmer@umassmed.edu.
The Effects of Vitamin D Supplementation on Hepatic Dysfunction, Vitamin D Status, and Glycemic Control in Children and Adolescents with Vitamin D Deficiency and Either Type 1 or Type 2 Diabetes Mellitus

Benjamin Udoka Nwosu1*, Louise Maranda2

1 Division of Endocrinology, Department of Pediatrics, University of Massachusetts Medical School, Worcester, Massachusetts, United States of America, 2 Department of Quantitative Health Sciences, University of Massachusetts Medical School, Worcester, Massachusetts, United States of America

Abstract

Background: The effects of vitamin D supplementation on mild hepatic dysfunction and glycemic control are unclear in children and adolescents with either type 1 (T1D) or type 2 diabetes (T2D).

Hypothesis: Vitamin D supplementation will improve hepatic dysfunction and glycemic control.

Aim: To determine the effect of vitamin D supplementation on alanine transaminase (ALT), hemoglobin A1c (HbA1c), and serum 25-hydroxyvitamin D [25(OH)D] concentration.

Subjects and Methods: A retrospective study of 131 subjects with either T1D (n = 88:46 females, 42 males), or T2D (n = 43:26 females, 17 males) of ages 3–18 years between 2007–2013. All subjects had (1) a diagnosis of diabetes for >12 mo, (2) received vitamin D supplementation for the management of vitamin D deficiency (3) had baseline and subsequent simultaneous measurements of HbA1c, ALT, and 25(OH)D. Vitamin D deficiency was defined as 25(OH)D concentration of < 50 nmol/L (20 ng/mL).

Results: At baseline, vitamin D deficiency occurred in 72.1% of patients with T2D and in 37.5% of T1D patients (p < 0.001). Patients with T2D had significantly higher values for BMI SDS (p < 0.001), alanine transaminase (ALT) (p = 0.001), but lower 25(OH)D (p < 0.001), and no difference in HbA1c (p = 0.94), and total daily dose (TDD) of insulin per kg body weight (p = 0.48) as compared to T1D patients. After 3 months of vitamin D supplementation, there was a significant increase in 25(OH)D in both T2D (p = 0.015), and T1D patients (p < 0.001); significant reduction in BMI SDS (p = 0.015) and ALT (p = 0.012) in T2D, but not in T1D. There was a clinically-significant decrease in HbA1c in T2D from 8.5 ± 2.9% at baseline to 7.7 ± 2.5 at 3 mo, but not in T1D, 8.5 ± 1.2 to 8.5 ± 1.1%.

Conclusions: Vitamin D supplementation in subjects with T2D was associated with statistically significant decreases in BMI SDS, ALT, and a clinically-significant decrease in HbA1c.

Introduction

The management of diabetes mellitus remains an enigma even though its symptoms were described more than 2000 years ago. This is because the central therapeutic goal of diabetes management, euglycemia, is influenced by complex physiologic and pathologic processes, some of which are clearly understood, while others are less clear. Suboptimal glycemic control is a recognized risk factor for acute and chronic complications of diabetes including microvascular and macrovascular diseases [1–3]. However, the role of comorbid states such as nonalcoholic fatty liver disease (NAFLD) and vitamin D deficiency on glycemic control in children and adolescents has not been fully elucidated. Poor glycemic control remains a growing problem in patients with type 1 (T1D) or type 2 diabetes (T2D) [4] despite improvements in insulin formulation, delivery and adjunctive therapies [5]. A recent national study reported that a high proportion of youth with diabetes had elevated hemoglobin A1c (HbA1c) values, with 17% of patients with TIDM and 27% of those with T2DM showing significantly poor control, defined as HbA1c ≥ 9.5% [4].

NAFLD is the most common form of liver dysfunction in children [6], and the leading cause of elevated liver enzymes in
Vitamin D and Glycemic Control in Children and Adolescents

Subjects and Methods

Ethics Statement

The study protocol was approved by the University of Massachusetts Institutional Review Board. All patient records and information were anonymized and de-identified prior to analysis.

Subjects

The clinical records of children and adolescents of ages 3–18 years who were treated for T1D and T2D at the Children’s Medical Center of the University of Massachusetts between 2007 and 2013 were reviewed. Subjects were included if they had a diagnosis of diabetes for >12 mo, had HbA1c and 25(OH)D obtained simultaneously, and were on no vitamin D or calcium supplements. Subjects were excluded if they had vitamin D or calcium supplementation at baseline, or the disorders of calcium metabolism, hemoglobinopathies, or malabsorption syndrome such as celiac disease. Eighty-eight subjects with T1D (46 females, 42 males) and 43 subjects with T2D (26 females and 17 males) fulfilled these criteria (Table 1). The diagnosis of T2D was based on fasting blood glucose of ≥7 mmol/L (126 mg/dL), and/or 2-hour postprandial glucose of ≥11.1 mmol/L (200 mg/dL), and/or random blood glucose of ≥11.1 mmol/L (200 mg/dL) with symptoms of polyuria and/or polydipsia. All patients with T2D had negative results for T1D-associated antibodies (insulin, islet cell, glutamic acid decarboxylase, and insulinoma associated-2).

Because 25(OH)D level could vary with sunlight exposure, we categorized each subject’s visit according to the seasons as follows: fall (September 22–December 21), winter (December 22–March 21), spring (March 22–June 21), and summer (June 22–September 21) [31]. All subjects with T1D received insulin only. Of the 43 patients with T2D, 17 patients received a combination of insulin and metformin, 15 patients received metformin only, while 8 patients received insulin monotherapy.

The Procedure for Vitamin D Therapy

The rationale for the vitamin D supplementation in these patients was based on recent reports of high prevalence of vitamin D deficiency in children and adolescents with either T1D or T2D [22,24,25]. It is the standard practice at the Children’s Medical Center to monitor the vitamin D status of children and adolescents with diabetes mellitus during patients’ yearly blood draw for the evaluation of complications of diabetes mellitus, or at one of the patients’ quarterly visits for routine diabetes care. Patients with serum 25(OH)D concentration of <50 nmol/L were started on vitamin D supplementation using either ergocalciferol or cholecalciferol with the aim of raising the 25(OH)D level to >75 nmol/L.

All participants received either ergocalciferol or cholecalciferol for a period ranging from 8 weeks for those receiving 7000 IU/day, through 12–16 weeks for subjects receiving 4000 IU/day as shown in Table 2. The dose of vitamin D was based on patient’s age and weight according to reports showing that 25(OH)D response to vitamin D supplementation is directly related to dose and body size [32].

Anthropometry

Height was measured to the nearest 0.1 cm using a wall-mounted stadiometer (Holtain Ltd, Crymych, Dyfed, UK). Weight was measured to the nearest 0.1 kg using an upright scale. Body mass index (BMI) was derived using the formula weight/height² (kg/m²), and expressed as SDS for age and gender based on the National Center for Health Statistics (NCHS) data [33].
Biochemical Studies

Data were collected from quarterly HbA1c estimation during clinic visits. Data on serum concentrations of alanine transaminase (ALT) were obtained simultaneously with HbA1c during routine clinic visit before and after vitamin D supplementation in both T1D and T2D patients. Specifically, ALT, 25(OH)D and other laboratory studies were estimated annually or bi-annually, as part of a routine screening protocol for complications of diabetes mellitus. Patients with vitamin D deficiency were started on vitamin D supplementation, and had a follow up laboratory evaluation for 25(OH)D level at their follow up quarterly visit. Vitamin D supplementation was either discontinued if vitamin D levels became normal upon retesting, or supplementation was continued for another cycle of treatment to attain normal vitamin D status. Data were collected on HbA1c levels obtained 3 months prior to the date of vitamin D supplementation, at the time of the initiation of vitamin D supplementation, and at +3mo, +6mo, and +9mo for the evaluation of the temporal effect of vitamin D supplementation on HbA1c levels.

Assays

Hemoglobin A1c was measured by DCA 2000+ Analyzer (Bayer, Inc., Tarrytown, NY, USA) based on Diabetes Control and Complications Trial standards [34]. Serum levels of 25(OH)D were analyzed using 25-hydroxy chemiluminescent immunoassay (DiaSorin Liaison; Stillwater, Minnesota), which has a 100% cross-reactivity with both metabolites of 25(OH)D namely, 25(OH)D2 and 25(OH)D3 and thus measures total serum 25(OH)D content. Its functional sensitivity is 10 nmol/L (4 ng/mL), and its intra- and inter-assay coefficients of variation are 5% and 8.2% respectively.

Vitamin D Status

Vitamin D sufficiency was defined as a 25(OH)D concentration ≥30 ng/mL (75 nmol/L); vitamin D insufficiency as 25(OH)D of 20 to 29.9 ng/mL (50 to 75 nmol/L); and vitamin D deficiency as 25(OH)D level <20 ng/mL (50 nmol/L) according to the Endocrine Society criteria [35].

Statistical Analyses

Statistical analyses were performed using the Predictive Analytics SoftWare v.21 (IBM Corporation, Armonk, NY).

| Table 1. Comparison of the characteristics of patients with type 1 diabetes vs. type 2 diabetes. |
|---|---|---|
| Parameters | Type 1 Diabetes (n = 88) | Type 2 Diabetes (n = 43) | p |
| Age (years) | 12.6±3.6 | 16.2±2.2 | <0.001 |
| Sex: males (%) | 42 (47.7%) | 17 (39.5%) | 0.38* |
| Race: white (Non-Hispanic) (%) | 73 (83.0%) | 23 (53.5%) | 0.001* |
| Height SDS (baseline) | 0.04±1.1 | 0.2±1.2 | 0.57 |
| Height SDS (3mo) | 0.04±1.1 | 0.04±1.2 | 1.0 |
| Weight SDS (baseline) | 0.69±1.0 | 2.3±0.9 | <0.001 |
| Weight SDS (3mo) | 0.71±1.0 | 2.3±1.0 | <0.001 |
| Body Mass Index SDS (baseline) | 0.80±0.9 | 2.2±0.6 | <0.001 |
| Body Mass Index SDS (3mo) | 0.81±0.8 | 2.14±0.7 | <0.001 |
| Alanine Transaminase (U/L) | 19.2±6.2 | 48.3±47.4 | 0.001 |
| 25(OH)D level (nmol/L) | 53.7±14.6 | 41.2±15.3 | <0.001 |
| 25(OH)D level (nmol/L) in Whites | 54.0±14.3 | 42.0±15.9 | 0.004 |
| Percentage Vitamin D Deficiency [25(OH)D <50 nmol/L] (%) | 33 (37.5%) | 31 (72.1%) | <0.001* |
| Hemoglobin A1c (%) | 8.5±1.2 | 8.5±2.9 | 0.94 |
| Seasons (Summer-Fall) | 50/88 (56.8%) | 17/43 (39.5%) | *0.063 |
| Duration of Diabetes Mellitus | 2.9±1.2 | 2.03±1.29 | 0.001 |

* = p values by Chi Square for proportions; SDS = standard deviation score; 25(OH)D = 25-hydroxyvitamin D.

doi:10.1371/journal.pone.0099646.t001

| Table 2. Summary of Patients’ Vitamin D Treatment Plan. |
|---|---|---|
| Treatment Plan | Number of Subjects |
| Dose of Vitamin D (IU/day) | Type 1 diabetes | Type 2 diabetes |
| <1000 | 3 | 1 |
| 1000–2000 | 81 | 26 |
| 4000 | 4 | 6 |
| 7000 | 0 | 10 |

doi:10.1371/journal.pone.0099646.t002
Means, standard deviations, and percentages were calculated for
descriptive summary statistics. The values for ALT were log
transformed before analysis to approximate normal distributions.
Comparisons between independent means were made using two-
tailed Student’s t test and ANOVA. Non-independent measures
over time were compared using paired t test and repeated-
measures ANOVA. Proportions were compared using Chi square
test; Fisher’s exact test was used where marginal totals were < 5.
Height, weight, and BMI were expressed as a standard deviation
score (SDS).

Power analysis. The study’s primary goal was to detect
significant changes in HbA1c in subjects with either T1D or T2D
during the 3 mo period of vitamin D supplementation, and
secondarily to determine if there was a persistence of the changes
in HbA1c over a 9 mo period. The small effect size of +0.03% change
in HbA1c during the 3 mo of vitamin D supplementation in the 88 subjects
with T1D yielded a power of 7.5%, while the clinically-significant effect size of −0.6% in 37 subjects with T2D who had pre- and post-treatment values for HbA1c yielded a power of 60.4% at a p value of 0.024. Further extrapolation showed that 1,982 subjects with T1D would be needed to achieve a power of 60.4%; while 3,175 patients with T1D, and 58 patients with T2D would be needed to achieve a power of 80%.

Results

One hundred and thirty one subjects of ages 3–18 years (male
15.8±3.4 years, female 13.7±3.8, p=0.80) were studied. This
consisted of 88 subjects (42 males, 46 females) with T1D of mean
age 12.6±3.6 years (males 13.1±3.5; females 12.1±3.6, p=0.23);
and 43 subjects (17 males, 26 females) with T2D of mean age
16.2±2.2 years (males 15.8±2.2; females 16.4±2.2, p=0.36)
(Table 1).

At baseline, 72.1% of patients with T2D had vitamin D
deficiency compared to 37.5% of T1D patients (p<0.001).
Patients with BMI SDS (2.2±0.6 vs. 0.80±0.9, p<0.001), ALT
(48.3±14.7 vs. 19.2±6.2, p=0.001), but lower mean 25(OH)D level
(41.2 nmol/L ±15.3 vs. 53.7±14.6, p<0.001), and no difference
in HbA1c (8.9±2.9% vs. 8.5±2.1, p=0.94) and total
daily dose (TDD) of insulin per kg body weight (0.85 units/kg
±0.4 vs. 0.88±0.3, p=0.48) (Table 3).

At 3 months, following vitamin D supplementation, 25(OH)D
increased significantly in patients with T1D from a baseline of
53.2±14.6 nmol/L to a peak of 67.6±20.6 at 3 mo, and then
decreased to 62.4±18.4 nmol/L (ANOVA p<0.001) (Figure 1).
Similarly, in patients with T2D, 25(OH)D rose significantly from
a baseline value of 41.8±15.0 nmol/L to a peak of 60.7±27.7 at 3
months and then subsequently decreased to 49.2±16.6 nmol/L
(ANOVA p<0.011). There was neither a change in the TDD of
insulin per kg body weight in either T1D or T2D, nor in the TDD
of metformin per kg body weight in T2D patients (Table 3).

Table 3. Comparison of the changes in the doses of insulin and
metformin during the period of vitamin D supplementation.

<table>
<thead>
<tr>
<th>Parameters</th>
<th>Type 1 Diabetes (n = 88)</th>
<th></th>
<th>Type 2 Diabetes (n = 43)</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Time (months)</td>
<td></td>
<td>0</td>
<td>3</td>
<td></td>
</tr>
<tr>
<td>TDD of insulin (units)</td>
<td></td>
<td>48.0±26.4</td>
<td>49.4±26.7</td>
<td>0.008</td>
</tr>
<tr>
<td>TDD of insulin per kg body weight (units/kg)</td>
<td></td>
<td>0.90±0.3</td>
<td>0.91±0.3</td>
<td>0.54</td>
</tr>
<tr>
<td>TDD of metformin (mg)</td>
<td></td>
<td>N/A</td>
<td>N/A</td>
<td></td>
</tr>
<tr>
<td>TDD of metformin per kg body weight (mg/kg)</td>
<td></td>
<td>N/A</td>
<td>N/A</td>
<td></td>
</tr>
</tbody>
</table>

TDD = total daily dose.
doi:10.1371/journal.pone.0099646.t003

Discussion

This study evaluated the effects of vitamin D supplementation
on hepatic dysfunction and glycemic control in children and
adolescents with vitamin D deficiency and either T1D or T2D. At
baseline, a greater proportion of subjects with T2D were obese,
and had both vitamin D deficiency and elevated ALT levels
compared to those with T1D. The 3-mo period of vitamin D
supplementation in subjects with T2D was associated with

An analysis of the anthropometric changes in the subjects
during the 3-month period of vitamin D supplementation showed
no differences in weight SDS in either the T1D (0.70±1.0 to
0.71±1.0, p=0.31) or T2D (2.31±0.96 to 2.26±0.96, p=0.13)
cohort. In contrast, there was a significant decrease in BMI SDS
in patients with T2D (2.21±0.62 to 2.14±0.66, p=0.015), but not in
patients with T1D (0.80±0.38 to 0.81±0.84, p=0.61).

A comparison of changes in HbA1c level over a period of 9 mo
from the time of the initiation of vitamin D supplementation in
subjects with either T1D or T2D showed a significant difference
in HbA1c between the subjects with T1D and those with T2D
(ANOVA p<0.011). A focused analysis of the changes in HbA1c
over the 9-month period showed a statistically significant, but
clinically non-significant increase in HbA1c from baseline to 9 mo
(p=0.001) in the T1D cohort, while the patients with T2D had no
change in A1c (p=0.52). A closer examination of the HbA1c
trends during the 9 mo showed that in patients with T1D, HbA1c
levels increased consistently over time from 8.5±1.2 through
8.9±1.2% (ANOVA p=0.001), while in patients with T2D, the
HbA1c value decreased at the beginning of the supplementation
(8.5±2.9% at baseline through 7.7±2.3% at 3 mo) but slowly
returned toward the baseline value of 8.2±2.3% at the end of 9
months (Figure 3). To investigate whether pre-treatment excur-
sions in HbA1c accounted for the changes in HbA1c described
above for T1D and T2D, we compared the mean of the HbA1c
levels drawn 3 mo before the start of vitamin D supplementation
to the mean of the baseline HbA1c drawn just before the start of
vitamin D therapy. There were no significant differences in
HbA1c values in T1D (8.4±1.3% vs. 8.5±1.2, p=0.57), and in
T2D (8.9±3.3 vs. 8.5±2.9, p=0.26).

Discussion

This study evaluated the effects of vitamin D supplementation
on hepatic dysfunction and glycemic control in children and
adolescents with vitamin D deficiency and either T1D or T2D. At
baseline, a greater proportion of subjects with T2D were obese,
and had both vitamin D deficiency and elevated ALT levels
compared to those with T1D. The 3-mo period of vitamin D
supplementation in subjects with T2D was associated with
significant reduction in BMI SDS, ALT, and a clinically-significant decrease in HbA1c which was followed by a gradual return toward pretreatment HbA1c values. These reductions in BMI SDS, ALT, and HbA1c [36] in T2D patients were not associated with significant changes in the doses of either insulin or metformin. These data and our earlier report [22] suggest that vitamin D deficiency may be associated with mild hepatic dysfunction which could in turn impair glycemic control in patients with T2D. The normalization of serum vitamin D concentration through vitamin D supplementation appeared to transiently improve glycemic control in patients with T2D.

Our data are in agreement with studies showing a higher prevalence of vitamin D deficiency in pediatric patients with T2D compared to those with T1D [37]. The clinically-significant reduction in HbA1c in our T2D cohort (Figure 2) is consistent with reports of significant associations between vitamin D and glycemic control in T2D [38], as well as earlier reports linking vitamin D deficiency with glucose intolerance [39], hyperinsulinemia [40], obesity [41], and T2D. This clinically-significant reduction in HbA1c in subjects with T2D is similar to the findings of a meta-analysis [36] on the effect of exercise on HbA1c in patients with T2D, which reported a decrease in HbA1c of 0.6%, with associated significant reductions in both visceral and subcutaneous adipose tissues in the study patients.

Vitamin D Deficiency and Type 1 Diabetes

Though vitamin D deficiency has been associated with increased risk of developing T1D [42,43], the relationship between 25(OH)D and glycemic control in patients with T1D is not fully understood. Our previous study [22] found no significant relationship between 25(OH)D and HbA1c in patients with T1D, while this study found a statistically significant, but clinically non-significant increase in HbA1c value following vitamin D supplementation. These results differ from the conclusions of a study in children, adolescents, and young adults with T1D which found a significant reduction in HbA1c level following a supplementation regimen consisting of both vitamin D and calcium [30]. It is possible that vitamin D alone has no significant role on improving glycemic control in patients with T1D.

Vitamin D Deficiency and Type 2 Diabetes

There is no consensus on the effect of vitamin D supplementation on HbA1c level in T2D. Even though previous studies [22,44,45] had reported strong inverse relationship between 25(OH)D and HbA1c, this association alone is not enough to demonstrate a cause and effect relationship. Evidence from two randomized controlled trials (RCT) suggests that vitamin D supplementation effectively reduces insulin resistance (IR) [46,47], but three smaller RCTs [48–50] of vitamin D supplementation in patients with T2D reported no change in HbA1c following vitamin D supplementation. A closer examination of these three
RCTs showed several limitations: (1) all three studies were underpowered (only 16–20 participants per arm), (2) only one study [50] was designed for glycemic outcomes, but it recruited only about half of the planned cohort, and studied patients with normal 25(OH)D levels; (3) only one study [48] reported baseline use of diabetes medications; however, in that study metformin use rate was much higher in the vitamin D arm; (4) changes in diabetes medications were not reported and were not taken into account in the analyses; and (5) all three trials used large infrequent doses of vitamin D. Two recent randomized studies reported improved glycemic control in patients with T2D who either received vitamin D alone [51] or vitamin D fortified yogurt drink [52] while another study reported decreased levels of inflammatory markers following vitamin D supplementation in patients with T2D [53]. However, a Japanese study reported no change in HbA1c following 2000 IU per day of vitamin D3 with calcium for 24 weeks in patients with T2D [54]. Thus, the effects of vitamin D supplementation on glycemic control in patients with T2D are unclear in adults, and more so in children and adolescents where there are only a few published studies.

There was a significant decrease in BMI SDS in patients with T2D following vitamin D supplementation. The high prevalence of obesity and vitamin D deficiency at baseline in subjects with T2D is consistent with a report that characterized vitamin D deficiency as a risk factor for obesity and T2D [55]. The decrease in BMI SDS concurs with earlier studies indicating that vitamin D repletion could potentiate weight loss and improve metabolic markers [47,56,57]. Vitamin D is believed to regulate adipocyte apoptosis leading to decreased fat mass [58,59]. This vitamin D-associated weight loss may have contributed to the significant decrease in ALT concentrations in our T2D cohort.

Vitamin D Deficiency and Alanine Transaminase

There was a significant decrease in ALT following vitamin D supplementation in patients with T2D compared to those with T1D. Several studies have reported an association between liver enzymes or calculated surrogate measures of NAFLD, such as fatty liver index, and the incidence of diabetes mellitus [13–16]. Recent studies suggest that NAFLD predicts prediabetes [12], and that the resolution of fatty liver could reduce the risk of incident diabetes mellitus [18]. We previously showed a strong inverse relationship between ALT and 25(OH)D in children and adolescents with T2D [22], while this present study reports a significant decrease in ALT levels in patients with T2D who received vitamin D supplementation for the management of hypovitaminosis D.

The mechanism of the transient, clinically-significant improvement in glycemic control in patients with T2D during the period of vitamin D supplementation is not clear. Vitamin D supplementation has been shown to improve β-cell function [23] and the augmentation of insulin synthesis and secretion once it is activated to its active form, 1,25-dihydroxyvitamin D, by 1α-hydroxylase enzyme which is expressed in β cells [60] [61–63]. This study however, suggests that an improvement in hepatic dysfunction, as shown by reduced ALT, could also be associated with an improved glycemic control.

One of the limitations of our study is its retrospective nature which could have introduced selection bias as only patients who fulfilled the inclusion and exclusion criteria were studied. We also
did not directly evaluate subjects’ compliance with their vitamin D therapy. However, the post-treatment vitamin D levels were significantly elevated in patients with either T1D or T2D. Another limitation was that the vitamin D supplementation was not continued for longer than three months, and thus it was unclear whether the effect of vitamin D supplementation on glycemic control could have been sustained over a longer period of time. The lack of a relationship between ALT and 25(OH)D in T1D patients may be due to the fact that a fewer number of patients with T1D had ALT measured as compared to the larger proportion of patients with T2D who had ALT values. Specifically, forty two (47.7%) of the patients with T1D, and 36 (83.7%) of the subjects with T2D had ALT measured at baseline, while 12 (13.6%) of T1D and 29 (67.4%) of the T2D patients had ALT values following vitamin D supplementation. Another reason for a lack of an association between ALT and 25(OH)D could be due to the fact that subjects with T1D had normal mean serum ALT concentration at baseline compared to patients with T2D.

The strengths of this study stem from the fact that both the patients with either T1D or T2D received their care within the same clinical system, which is located in a similar geographical area around latitude 42° N, thus ensuring similar levels of insolation around the year. We had a relatively good sample size to enable us determine the differences in the various parameters studied. The availability of post-treatment 25(OH)D values confirmed that the subjects received the interventional therapy, while the availability of serial HbA1c values enabled us to establish a longitudinal model for the investigation of the duration of the glycemic effects of vitamin D supplementation on HbA1c and ALT in both T1D and T2D. Even though this is a retrospective study, it provides the much needed data on the effect of routine vitamin D supplementation on HbA1c, 25(OH)D, and ALT values in children and adolescents with either T1D or T2D. Such data will help establish the rationale for further investigation on the effects of vitamin D supplementation on these parameters in children and adolescents with diabetes mellitus.

**Conclusions**

This study demonstrates that routine vitamin D supplementation in patients with diabetes mellitus is associated with a significant reduction in BMI SDS, ALT, and an initial, clinically-significant reduction in HbA1c in patients with T2D, but not T1D. The changes in these parameters were not associated with significant changes in the doses of either insulin or metformin. Even though these findings suggest that vitamin D deficiency could impair hepatic processes that promote β-cell function and glycemic control in patients with T2D; and that this hepatic dysfunction could be ameliorated by vitamin D supplementation with resultant improvement in glycemic control, our data are not adequate to confirm these conclusions. Further randomized controlled trials are warranted to determine the effect of vitamin D supplementation on glycemic control in T2D, and the optimal
dose of adjunctive vitamin D therapy for the maintenance of long-term glycemic control in children and adolescents with diabetes mellitus.

Acknowledgments

BUN is a member of the UMass Diabetes and Endocrine Research Center (DK32520). We thank Mr. Francis M. Wanjau for his help with data management, and Ms. Jessica L. Kowaleski for her clerical assistance.

References


